Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verastem Inc (NQ: VSTM )

9.215 -0.095 (-1.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 71,213
Open 9.130
Bid (Size) 9.000 (1)
Ask (Size) 10.12 (1)
Prev. Close 9.310
Today's Range 9.020 - 9.380
52wk Range 4.260 - 15.18
Shares Outstanding 25,295,495
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire

Performance

YTD
+11.02%
+11.02%
1 Month
-20.49%
-20.49%
3 Month
-22.50%
-22.50%
6 Month
+36.52%
+36.52%
1 Year
+105.38%
+105.38%

More News

Read More
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Recap: Verastem Q4 Earnings
Via Benzinga
Where Verastem Stands With Analysts
Via Benzinga
VSTM Stock Earnings: Verastem Misses EPS for Q4 2023
Via InvestorPlace
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
From Verastem Oncology
Via Business Wire
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
From Verastem Oncology
Via Business Wire
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
From Verastem Oncology
Via Business Wire
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
From Verastem Oncology
Via Business Wire
Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
From Verastem Oncology
Via Business Wire
3 Off-the-Beaten-Path Stocks Poised for Substantial Growth
Via InvestorPlace
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential
Via InvestorPlace
New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population
From Verastem Oncology
Via Business Wire
Verastem Oncology Strengthens Executive Leadership Team with Key Appointments
From Verastem Oncology
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.